Stock data
Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc. (ENTA) reported revenue of US$65.32M and net income of -US$81.89M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-09-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$65.32M | — | -US$85.35M | -US$81.89M | — |
| 2024 | US$67.64M | — | -US$121.69M | -US$116.05M | — |
| 2023 | US$79.20M | — | -US$137.21M | -US$133.82M | — |
| 2022 | US$86.16M | — | -US$123.84M | -US$121.75M | — |
| 2021 | US$97.07M | — | -US$109.57M | -US$79.00M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$14.36M | -US$19.50M | — |
| 2026-03-31 | US$17.16M | -US$13.09M | — |
| 2025-12-31 | US$18.61M | -US$11.94M | — |
| 2025-09-30 | US$15.12M | -US$18.70M | — |
| 2025-06-30 | US$18.31M | -US$18.25M | — |
| 2025-03-31 | US$14.93M | -US$22.64M | — |
| 2024-12-31 | US$16.96M | -US$22.29M | — |
| 2024-09-30 | US$14.61M | -US$28.82M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.